EP1: Multi-Site, Multi-Insight: Strategic Site Identification and Expanded Patient Access in Clinical Trials

EP3: The Future of Sampling Is Here—Almost

Host Lisa Sanford is joined by Neil Spooner (PCSIG), Katty Wan (Pfizer), Enaksha Wickremsinhe (Gates Medical Research Institute), and Jeff Plomley (Altasciences) to discuss microsampling and the role it plays in a patient-centric sampling approach. With reduced sample volume, as well as the ability to provide additional options and convenience to patients, this episode showcases the “big” potential and impact of this innovative “small” technique. From training, logistical, and implementation challenges, to regulations and device dependency, learn more about the building momentum in both bioanalytical and clinical applications.

EP2: A Changing Drug Development Paradigm

Automation? Personalized medicine? A shifting talent pool? Dive into the rapidly changing world of drug development and listen to experts give their boldest predictions for the future of CROs. Host Lisa Sanford is joined by colleagues from Altasciences, Marie-Hélène Raigneau, CEO; Steve Mason, Co-COO; and Dr. Gaetano Morelli, Executive Vice President Medical Affairs and Chief Medical Officer; as they take a wide-angle look at the forces reshaping drug development today and predict what’s coming next for CROs, sponsors, and patients. From emerging AI applications to organ-on-a-chip technology, shifting talent dynamics, changes in day-to-day operations, and the possible rise of personalized medicine, their discussion explores how innovation is unfolding across the industry. About Off-Label With Altasciences: Off-Label presents candid conversations about the drug development industry from an insider perspective. We discuss trending topics and new developments alongside industry experts. Whether you’re drug development-curious or a seasoned veteran, enjoy as we peel back the label.

EP1: Multi-Site, Multi-Insight: Strategic Site Identification and Expanded Patient Access in Clinical Trials

Learn about the multiple benefits that incorporating a multi-site approach can provide in early-phase clinical research, the “red and green flags” to look out for when working with a CRO, the importance of the “non-data stuff.” Host Lisa Sanford is joined by Kat Connors, Director, Multi-Site Clinical Trial and Strategic Operations at Altasciences, as they discuss the momentum growing behind using a multi-site strategy, with a notable uptick in demand in the last few years. With multi-site solutions enabling access to more robust trial data, access to an expanded patient network, the opportunity to simultaneously work with specialty and healthy population branches, as well as improved trial efficiency, there is certainly more than one reason to tune in to this episode and hear more from their conversation! About Off-Label With Altasciences: About Off-Label With Altasciences:Off-Label presents candid conversations about the drug development industry from an insider perspective. We discuss trending topics and new developments alongside industry experts. Whether you’re drug development-curious or a seasoned veteran, enjoy as we peel back the label.

Introducing Off-Label With Altasciences

We’ve got some exciting news to share… We’re launching a new podcast called Off-Label! Host Lisa Sanford is peeling back the label on drug development to discuss trending topics and new advancements alongside industry experts—offering a candid insider’s perspective.Coming soon!